News Chart Arch Biopartners Inc.

Equities

ACHFF

CA03938C1041

Market Closed - OTC Markets Other stock markets 20:52:36 17/06/2024 BST			5-day change	1st Jan Change
1.21 ^USD	-1.63%		-6.20%	+8.37%

01:35pm	Arch Biopartners Announces University of Calgary Ethics Approval to Proceed with Phase II Trial for LSALT Peptide Targeting Cardiac Surgery Associated-Acute Kidney Injury (CS-AKI)	CI
05-31	Arch Biopartners Inc. Reports Earnings Results for the Second Quarter and Six Months Ended March 31, 2024	CI

0d9f5484159f62c20.UL3f_yflf-96empKeH-LVbIXvhrYfs-khPHJUYbVvNU.Ao3vvnWoJ9cgEQN9OxLKGIVnyWmXLYLOvZesfNK43uMziIqmU6kFnklXHQ~92a3dc939736dca22b143902e53df959